HeartFlow CEO John Farquhar Unloads 38,900 Shares in Stock Sale Worth Roughly $1.8 Million

HeartFlow, Inc. (NASDAQ:HTFL) disclosed in a September 14, 2026 SEC Form 4 filing that its Chief Executive Officer, John C.M. Farquhar, sold 38,900 shares of the company’s common stock. Based on the weighted average sale price reported in the filing, the transaction totaled approximately $1.8 million.

The sale came shortly after the stock touched a 52-week high. Shares closed at $49.88 on September 11, 2026, the trading day preceding the filing. In Tuesday’s session, HTFL changed hands around $48.91, down about 4.1% from the prior close of $51.00.

Executive stock sales are common and, on their own, do not signal anything about a company’s outlook — insiders sell shares for many reasons, including diversification, tax obligations, and prearranged trading plans. Still, filings under Section 16 of the Securities Exchange Act require prompt disclosure of insider transactions, making Form 4 documents a widely watched data point for investors tracking management’s activity.

About HeartFlow

HeartFlow is a medical technology company focused on non-invasive diagnosis and management of coronary artery disease. Its flagship platform applies artificial intelligence and computational fluid dynamics to generate personalized 3D models of a patient’s heart, aiming to reduce the need for invasive diagnostic procedures.

The company, which operates in the health information services industry, reported trailing 12-month revenue of $212.1 million and carries a market capitalization of roughly $2.2 billion based on current trading levels. The company continues to invest heavily in research and development as it scales its AI-driven cardiac diagnostics platform, consistent with a growth-stage profile in the healthcare technology sector.

The disclosure drew attention in part because of its timing: the sale followed the stock’s recent climb to a 52-week high, a milestone that often coincides with heightened insider activity as executives take advantage of appreciated share prices.

What to watch

• Any subsequent Form 4 filings from HeartFlow insiders, which would indicate whether further executive selling occurs.
• HeartFlow’s next quarterly earnings report, including revenue growth and research spending trends.
• Whether HTFL shares hold near their 52-week high or pull back further from recent levels.
• Updates on adoption of the HeartFlow Platform across hospital systems in the U.S. and international markets.

Source: original release